Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ectopic P granules protein 5 homolog (EPG5) is a large metazoan-specific coiled-coil protein (~290 kDa) that functions as a tethering factor in macroautophagy, specifically mediating the fusion between autophagosomes and lysosomes to ensure specificity and prevent mistargeting. EPG5 interacts preferentially with the GABARAP subfamily of ATG8 proteins through unique tandem LC3-interacting regions (LIR motifs) to facilitate and regulate autophagosome–lysosome fusion. Deficiency in EPG5 leads to mistargeting, impaired autophagic flux, and accumulation of dysfunctional vesicles, contributing to the pathogenesis of Vici syndrome—a severe multisystem disorder affecting brain, immune system, heart, skin, and eyes. EPG5 also plays a role in cellular immune responses to intracellular pathogens. There are currently no drugs targeting EPG5 directly, and mutations are primarily relevant as diagnostic biomarkers for Vici syndrome.
Not applicable; no drugs specifically modulate EPG5 function as a primary target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ectopic P granules protein 5 homolog (EPG5).